151 related articles for article (PubMed ID: 27060269)
1. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
[TBL] [Abstract][Full Text] [Related]
3. Polymer-free amphilimus-eluting stent versus biodegradable polymer biolimus-eluting stent in patients with and without diabetes mellitus.
Godino C; Pivato CA; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Milazzo D; Parisi R; Nicolino A; Moshiri S; Aprigliano G; Palloshi A; Zavalloni Parenti D; Rutigliano D; Locuratolo N; Melillo F; Scotti A; Arrigoni L; Montorfano M; Fattori R; Presbitero P; Sardella G; Bedogni F; Margonato A; Briguori C; Colombo A;
Int J Cardiol; 2017 Oct; 245():69-76. PubMed ID: 28874301
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
[TBL] [Abstract][Full Text] [Related]
5. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
[TBL] [Abstract][Full Text] [Related]
6. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
[TBL] [Abstract][Full Text] [Related]
7. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
8. Midterm and one-year outcome of amphilimus polymer free drug eluting stent in patients needing short dual antiplatelet therapy. Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTer rEgistry).
Godino C; Chiarito M; Donahue M; Testa L; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Briguori C; Margonato A; Colombo A
Int J Cardiol; 2017 Mar; 231():54-60. PubMed ID: 28104306
[TBL] [Abstract][Full Text] [Related]
9. One-year outcomes of polymer-free amphilimus-eluting stents versus durable polymer zotarolimus-eluting stents in patients with diabetes mellitus: a meta-analysis.
Wang H; Xie X; Zu Q; Lu M; Chen R; Yang Z; Gao Y
Cardiovasc Diabetol; 2022 Oct; 21(1):220. PubMed ID: 36307791
[TBL] [Abstract][Full Text] [Related]
10. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis.
Rozemeijer R; van Muiden IG; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Doevendans PA; Voskuil M; Stella PR
Catheter Cardiovasc Interv; 2019 Jul; 94(1):61-69. PubMed ID: 30604493
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
12. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Polymer-Free Drug-Eluting Stents.
Chiarito M; Sardella G; Colombo A; Briguori C; Testa L; Bedogni F; Fabbiocchi F; Paggi A; Palloshi A; Tamburino C; Margonato A; Pivato CA; Baber U; Calcagno S; Giordano A; Godino C; Stefanini GG
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007311. PubMed ID: 30767663
[TBL] [Abstract][Full Text] [Related]
14. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
15. Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Musto C; Berti S; Dibié A; Maupas E; Antoniucci D; Schofer J
Int J Cardiol; 2020 Feb; 301():50-55. PubMed ID: 31759686
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of the amphilimus-eluting polymer-free stent for chronic total occlusion treatment: a multicentre experience.
Maeremans J; Cottens D; Azzalini L; Pereira B; Godino C; Carlino M; Colombo A; Frambach P; Bellini B; Candilio L; Briguori C; Pierri A; Lamers S; Roux L; Duponselle J; Vrolix M; Dens J
J Cardiovasc Med (Hagerstown); 2018 Oct; 19(10):564-570. PubMed ID: 30124545
[TBL] [Abstract][Full Text] [Related]
17. Impact of Insulin-Treated and Noninsulin-Treated Diabetes Mellitus in All-Comer Patients Undergoing Percutaneous Coronary Interventions With Polymer-Free Biolimus-Eluting Stent (from the RUDI-FREE Registry).
Pepe M; Sardella G; Stefanini GG; Corcione N; Nestola PL; Morello A; Briguori C; Tamburino C; Fabbiocchi F; Rotolo FL; Tomai F; Paggi A; Lombardi M; Gioffrè G; Sclafani R; Rolandi A; Sciahbasi A; Scardaci F; Signore N; Mancone M; Giordano A
Am J Cardiol; 2019 Nov; 124(10):1518-1527. PubMed ID: 31547997
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
19. Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up.
Wiemer M; Stoikovic S; Samol A; Dimitriadis Z; Ruiz-Nodar JM; Birkemeyer R; Monsegu J; Finet G; Hildick-Smith D; Tresukosol D; Novo EG; Koolen JJ; Barbato E; Danzi GB;
Cardiovasc Diabetol; 2017 Feb; 16(1):23. PubMed ID: 28183306
[TBL] [Abstract][Full Text] [Related]
20. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
